Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Researchers investigated the safety and feasibility of discontinuing tyrosine kinase inhibitor (TKI) therapy in a select group of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who have achieved complete molecular response (CMR) without undergoing allogeneic stem cell transplantation. The study retrospectively analyzed 14 patients, finding that 79% maintained treatment-free remission after TKI discontinuation, particularly those with a CMR duration exceeding 48 months.